Skip to main content

Advertisement

SpringerLink
Log in

HE4: a new potential early biomarker for the recurrence of ovarian cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Human epididymis protein 4 (HE4) has recently been described as a new marker for the early diagnosis of ovarian cancer (OC). The objective of this study was to evaluate (a) the expression of HE4 vs. OC mucin CA125 in 32 patients with OC compared to 163 patients with other malignant or benign pathologies (b) HE4 as indicator of the recurrence of the disease in eight patients followed-up for 20 months after OC diagnosis. Serum HE4 and CA 125 levels were determined by ELISA and IRMA, respectively. At diagnosis, the patients with OC demonstrated high levels of both biomarkers with 96.9% sensitivity for HE4 and 85.7% for CA125. In the other pathologies there was 3.7% positivity for HE4 and 21.0% for CA125. The follow-up study showed an increase of HE4 5–8 months before CA125 increment in five of the eight patients, this early expression being strictly associated to a relapse of the disease. In conclusion, this study showed that HE4, compared to CA125, potentially is a better marker for the diagnosis of OC and could be an important early indicator of the recurrence of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol. 2002;20:1161–3.

    PubMed  Google Scholar 

  2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827–41.

    Article  CAS  PubMed  Google Scholar 

  3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–6.

    Article  PubMed  Google Scholar 

  4. Haries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 2002;3:529–36.

    Article  Google Scholar 

  5. Pecorelli S, Creasman WT, Petterson F, Benedet JL, Shepard JH. FIGO annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostat. 1988;3:75–102.

    Google Scholar 

  6. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99:267–77.

    Article  CAS  PubMed  Google Scholar 

  7. Bast Jr RC, Badgwell D, Marquez LR, Rosen D, Liu J, Baggerly KA, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15:274–81.

    Article  PubMed  Google Scholar 

  8. Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic mass. Obstet Gynecol. 1988;72:23–7.

    CAS  PubMed  Google Scholar 

  9. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009;142:99–05.

    CAS  PubMed  Google Scholar 

  10. Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, et al. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer. 2009;115:1395–403.

    Article  CAS  PubMed  Google Scholar 

  11. Urban N, McIntosh M, Andersen M, Karlan B. Ovarian cancer screening. Hematol Oncol Clin North Am. 2003;17:989–05.

    Article  PubMed  Google Scholar 

  12. Kirchhoff C. Molecular characterization of epididymal proteins. Rev Reprod. 1998;3:86–5.

    Article  CAS  PubMed  Google Scholar 

  13. Bingle L, Singleton V, Bingle CD. The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21:2768–73.

    Article  CAS  PubMed  Google Scholar 

  14. Clauss A, Lilja H, Lundwall A. The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun. 2005;333:383–9.

    Article  CAS  PubMed  Google Scholar 

  15. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acid protein. Biochem J. 2002;368:233–42.

    Article  CAS  PubMed  Google Scholar 

  16. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162–9.

    Article  CAS  PubMed  Google Scholar 

  17. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004;95:9–15.

    Article  CAS  PubMed  Google Scholar 

  18. Galgano MT, Hampton GM, Frierson Jr HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847–53.

    CAS  PubMed  Google Scholar 

  19. Moore RG, Brown AK, Miller MC, Kates S, Allard WJ, Verch MS, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–8.

    Article  CAS  PubMed  Google Scholar 

  20. Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Allard J, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrial adenocarcinoma of the uterus. Gynecol Oncol. 2008;108:196–201.

    Article  Google Scholar 

  21. Schink JC. Current initial therapy of stage II and IV ovarian cancer: challenges for managed care. Sem Oncol. 1999;26:2–7.

    CAS  Google Scholar 

  22. Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, et al. Hormonal risk factors for ovarian. Am J Epidemiol. 2008;167:1059–69.

    Article  PubMed  Google Scholar 

  23. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Tuxen TGC, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15:679–91.

    Article  CAS  PubMed  Google Scholar 

  24. Hellerstrom I, Hellerstron KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol. 2008;622:15–21.

    Article  Google Scholar 

  25. Allard J, Somers E, Theil R, Moore RG. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer. Annual meeting of the ASCO 2008 Abstract.

  26. Carroll JC, Cremin C, Allanson J, Blaine SM, Dorman H, Gibbons CA, et al. Hereditary breast and ovarian cancers. Can Fam Physician. 2008;54:1691–2. Review.

    PubMed  Google Scholar 

  27. Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode E, Thiel F, et al. Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol. 2009;3:171–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study is founded by The University of Rome “Sapienza”. We are thankful to Barbara Colaprisca and Silvestra Tudini for their technical assistance, to Prof. Mauizio Sensi, Prof. Susanna Morano and Claudio Tiberti for helpful comments and discussion, and Prof. Bruno Annibale for his contribution to the statistical work.

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Department of Oncology, University “Sapienza”, Viale Regina Elena 324, 00161, Rome, Italy

    Emanuela Anastasi, Giulia Giovanna Marchei, Valentina Viggiani, Giuseppina Gennarini, Luigi Frati & Maria Gabriella Reale

Authors
  1. Emanuela Anastasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giulia Giovanna Marchei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valentina Viggiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppina Gennarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luigi Frati
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Gabriella Reale
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emanuela Anastasi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anastasi, E., Giovanna Marchei, G., Viggiani, V. et al. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol. 31, 113–119 (2010). https://doi.org/10.1007/s13277-009-0015-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-009-0015-y

Keywords

Search

Navigation